Germline breast cancer susceptibility genes, tumor characteristics, and survival

Peh Joo Ho 1,2, Alexis J. Khng 1, Hui Wen Loh 1, Weang-Kee Ho 3, Cheng Har Yip 5, Nur Aishah Mohd-Taib 6,7, Veronique Kiak Mien Tan 8,9, Benita Kiat-Tee Tan 10, Su-Ming Tan 11, Ern Yu Tan 12,13,14, Swee Ho Lim 15, Suniza Jamaris 6,7, Yirong Sim 8,9, Fuh Yong Wong 16, Joanne Ngeow 17,18,19, Elaine Hsuen Lim 20, Mei Chee Tai 4, Eldarina Azfar Wijaya 4, Soo Chin Lee 21, Ching Wan Chan 22, Shaik Ahmad Buhari 22, Patrick M. Y. Chan 12, Juliana J. C. Chen 12, Jaime Chin Mui Seah 11, Wai Peng Lee 11, Chi Wei Mok 11, Geok Hoon Lim 15, Evan Woo 15, Sung-Won Kim 23, Jong Won Lee 24, Min Hyuk Lee 25, Sue K. Park 26,27,28, Alison M. Dunning 29, Douglas F. Easton 29,30, Marjanka K. Schmidt 31, Soo-Hwang Teo 32, Jingmei Li 1,33*, and Mikael Hartman 2,22,33†

Abstract

Background: Mutations in certain genes are known to increase breast cancer risk. We study the relevance of rare protein-truncating variants (PTVs) that may result in loss-of-function in breast cancer susceptibility genes on tumor characteristics and survival in 8852 breast cancer patients of Asian descent.

Methods: Gene panel sequencing was performed for 34 known or suspected breast cancer predisposition genes, of which nine genes (ATM, BRCA1, BRCA2, CHEK2, PALB2, BARD1, RAD51C, RAD51D, and TP53) were associated with breast cancer risk. Associations between PTV carrier ship in one or more genes and tumor characteristics were examined using multinomial logistic regression. Ten-year overall survival was estimated using Cox regression models in 6477 breast cancer patients after excluding older patients (≥75 years) and stage 0 and IV disease.

Results: PTV9genes carrier ship (n = 690) was significantly associated (p < 0.001) with more aggressive tumor characteristics including high grade (poorly vs well-differentiated, odds ratio [95% confidence interval] 3.48 [2.35–5.17], moderately vs well-differentiated 2.33 [1.56–3.49]), as well as luminal B [HER2−] and triple-negative subtypes (vs luminal A 2.15 [1.58–2.92] and 2.85 [2.17–3.73], respectively), adjusted for age at diagnosis, study, and ethnicity. Associations with grade and luminal B [HER2−] subtype remained significant after excluding BRCA1/2 carriers.

PTV25genes carrier ship (n = 289, excluding carriers of the nine genes associated with breast cancer) was not associated with tumor characteristics. However, PTV25genes carrier ship, but not PTV9genes carrier ship, was suggested to be associated with worse 10-year overall survival (hazard ratio [CI] 1.63 [1.16–2.28]).

* Correspondence: lijm1@gis.a-star.edu.sg
† Jingmei Li and Mikael Hartman contributed equally to this work.
1 Genome Institute of Singapore, Human Genetics, Singapore, Singapore
3 Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusions: PTV genes carriership is associated with more aggressive tumors. Variants in other genes might be associated with the survival of breast cancer patients. The finding that PTV carriership is not just associated with higher breast cancer risk, but also more severe and fatal forms of the disease, suggests that genetic testing has the potential to provide additional health information and help healthy individuals make screening decisions.

Keywords: Breast cancer, Protein-truncating variants, Overall survival

Background
Breast cancer is the most common cancer among women worldwide. Breast cancer manifestations are biologically and molecularly heterogeneous with a high degree of diversity observed between and within tumors. Such phenotypic differences in tumor characteristics are clinically informative because they are prognostic and can improve therapy selection [1, 2]. In particular, profiling of breast cancer can be based on the expressions of three immunohistochemical markers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2). Patients with ER- and PR-positive breast cancer respond well to endocrine therapy and have favorable outcomes [1]. In contrast, tumors which were ER/PR and HER2 negative are associated with worse survival and are typically treated with chemotherapy and radiotherapy [1].

There is a strong genetic component to the risk of breast cancer [3]. A large majority of disease-associated variants in susceptibility genes are protein-truncating variants (PTVs), a class of variants that usually results in an absence of functional protein [4]. Pathogenic PTVs are typically rare (allele frequency <1%) and are usually associated with a twofold or higher risk of breast cancer [5].

Previously, Li et al. [6] observed, in a study of 5099 Swedish breast cancer patients, that tumors arising in PTV carriers with known or suspected predisposition genes were phenotypically more aggressive and had worse survival as compared to tumors in non-carriers. However, there is growing concern that genetic markers identified in populations of predominantly European ancestry may not be equally informative in non-European populations, due to the modifier effect of lifestyle and genetic factors which may be distributed differently in diverse populations [7]. Here, we attempt to study how rare variants in breast cancer predisposition genes are associated with tumor characteristics and survival in 8852 breast cancer patients of Asian descent.

Methods
Study populations
The study population was derived from the patients enrolled in the Singapore Breast Cancer Cohort (SGBCC), the Malaysian Breast Cancer Genetic Study (MyBrCa), and the Korean Hereditary Breast Cancer Study (KOHBRA).

Singapore Breast Cancer Cohort (SGBCC)
The Singapore Breast Cancer Cohort (SGBCC) study includes women aged 21 years and above diagnosed with either breast carcinoma in situ or invasive breast cancer at one of the six participating restructured hospitals in Singapore (National University Hospital, KK Women’s and Children’s Hospital, Tan Tock Seng Hospital, Singapore General Hospital, National Cancer Centre Singapore, Changi General Hospital). These six hospitals collectively diagnose and treat ~76% of all breast cancer cases in Singapore [8]. Patients were a mixture of prevalent and incident cases from the three main ethnic groups, Chinese (81%), Malay (13%), and Indian (6%). Ethnicity was self-reported. According to the 2010 census of Singapore, Indian ethnicity refers “to persons of Indian, Pakistani, Bangladeshi or Sri Lankan origin such as Tamils, Malayalis, Punjabis, Bengalis, Singhalese, etc.” The ethnic distribution of SGBCC is similar to that of the general population of Singapore (Chinese 75.9%, Malay 15%, Indian 7.5%, Department of Statistics Singapore). Between April 2010 and December 2016, 7768 breast cancer patients were recruited into SGBCC. Of which 4538 patients had genetic information from blood or saliva samples collected at recruitment. After excluding duplicated individuals (n = 9), 4529 patients were included to test for associations between PTV carriership and tumor characteristics. A subset of 3213 patients were eligible for survival analysis.

The Malaysian Breast Cancer Genetic Study (MyBrCa)
The Malaysian Breast Cancer Genetic Study (MyBrCa), a hospital-based case-control study, was initiated in 2002 (described by Tan et al. [9]). Briefly, all patients diagnosed with breast cancer from two participating hospitals in Selangor, Malaysia (University Malaya Medical Centre, a public hospital, and Subang Jaya Medical Centre, a private hospital), were invited to participate. Participants were mainly from urban areas. These two hospitals treat more than 10% of the breast cancer cases in Malaysia [9]. The core ethnic groups of MyBrCa are Chinese (69%), Malay (16%), and Indian (12%). In Malaysia, the predominant ethnic group is Malay

Malay...
(67.4%), followed by Chinese (24.6%) and Indian (7.3%) (Department of Statistics Malaysia Official Portal). At recruitment, all participants \( n = 3822 \) provided a blood or saliva sample and completed a detailed questionnaire that included lifestyle and reproductive-related factors for breast cancer as well as personal and family history of cancer. We excluded 46 related samples and 15 duplicated samples, resulting in 3761 patients included in the study of associations between PTV carriership and tumor characteristics. A subset of 3264 patients were eligible for survival analysis.

**The Korean Hereditary Breast Cancer Study (KOHBRA)**

The KOHBRA study is a prospective hereditary breast cancer cohort in Korea [10]. Between May 2007 and May 2010, the KOHBRA study recruited 1967 subjects from 35 hospitals registered in the Korean Breast Cancer Society. All participants received genetic counseling and BRCA genetic testing; the clinical information and blood samples for blood banking were collected. Included in the study were patients with a family history of breast or ovarian cancers, patients with non-familial breast and ovarian cancer but with other risk factors of genetic disease, and family members of breast cancer patients with \( BRCA1/2 \) mutations [11]. Patients with information on PTVs \( n = 562 \) were included in the study of associations between PTV carriership and tumor characteristics. The KOHBRA study was omitted from the survival analysis as it is a \( BRCA1/2 \) case-control study oversampling \( BRCA1/2 \) carriers, which will result in a survival bias in our PTV carriership analysis if included.

**Demographic information**

Self-reported ethnicity (Chinese, Malay, Indian, and others) and family history of breast cancer (yes, no) were obtained from structured questionnaires, in SGBCC and MyBrCa. All participants from KOHBRA were Koreans and family history was obtained from a structured questionnaire.

**Clinical data for breast cancer patients**

Clinical characteristics were extracted from hospital breast cancer registries or hospital medical records—age at diagnosis (years), tumor stage \( (0, I \text{--IV}) \), tumor size \( (< 2 \text{ cm}, 2 \text{--}5 \text{ cm}, \text{and} >5 \text{ cm}, \text{similar to TNM size reported by AJCC version 7}) \), nodal status (positive, negative), tumor grade (well-differentiated, moderately differentiated, and poorly differentiated), and immunohistochemical markers ER, PR, and HER2. For ER status and PR status, staining of \( \geq 1\% \) was considered positive. HER2 status was classified as positive or negative (includes equivocal). Intrinsic-like subtypes were defined using immunohistochemical markers for ER, PR, and HER2 in conjunction with histologic grade: luminal A \([\text{ER}+/\text{PR}+,\text{HER2}−,\text{well- or moderately differentiated}],\text{luminal B [HER2}−\text]{[ER}+/\text{PR}+,...\text{HER2}−,\text{and poorly differentiated], luminal B [HER2}+]\text{[ER}+/\text{PR}+,\text{HER2}+,\text{and poorly differentiated], HER2-enriched [HER2}+]\text{, triple-negative [ER}−,\text{PR}−,\text{and HER2}−]...\text{[12]}\).

Treatment data, for SGBCC and MyBrCa, were extracted from hospital breast cancer registries or hospital medical records—surgery (yes, no), neo-adjuvant and/or adjuvant chemotherapy (yes, no), radiotherapy (yes, no), endocrine therapy (yes, no), and trastuzumab therapy (yes/no).

**Targeted sequencing**

DNA isolation was performed according to the manufacturer’s instructions for buffy coat (FlexiGene DNA kit, Qiagen, or Promega’s Maxwell 16 Blood DNA Purification Kit) in SGBCC and MyBrCa, and G-DEX(TM) II Genomic DNA extraction kit (Intron) in KOHBRA. DNA isolation for saliva samples (only in SGBCC) was performed using Oragene and preplIT+L2P reagent, DNA Genotek.

Target-enriched sequencing libraries of germline DNA for the breast cancer cases and controls were prepared at the Centre for Cancer Genetic Epidemiology (University of Cambridge) as part of a larger effort (Breast Cancer Risk after Diagnostic Gene Sequencing, BRIDGES, [https://bridges-research.eu]) [13]. The gene panel, which was developed as part of the BRIDGES initiative, included coding sequences and intron/exon boundaries for a total of 34 genes for which there was prior evidence of association with breast cancer risk, including genes offered on commercial panels for breast cancer in early 2016 (Additional file 1: Table S1). The targeted sequencing workgroup in BRIDGES first performed rare variant detection in preliminary gene panels combined with data from whole-exome sequencing data- sets before arriving at the 34 genes selected for the BRIDGES panel. Details of the library preparation, sequencing, variant calling, and quality control methods are given in Dorling et al. [13].

**Protein-truncating variant (PTV) carriership**

In this study, PTVs were defined as (1) variants predicted to introduce a premature stop codon (frameshift or nonsense mutations), (2) small insertions or deletions (indels) predicted to disrupt a transcript’s reading frame, or (3) splice site mutations. PTVs occurring in the last exon of each gene were excluded to avoid including variants that do not lead to nonsense-mediated decay. Variants with less than 1% frequency in our study population were included. A list of PTVs from the 34 genes sequenced is listed in Additional file 1: Table S2. The distribution of PTVs in unselected breast cancer patients from SGBCC and MyBrCa was visualized in oncoplot
and bar chart (Additional file 1: Fig. S1). As the PTVs are rare [14], the number of carriers in most genes was too small to analyze individually. Hence, we aggregated PTVs for each individual, creating a single binary variable: carrier of at least one PTV in any gene versus non-carrier. We hypothesized that the effects of PTVs on subtype and outcome were likely to be in the same direction and therefore the power to detect an association with this burden variable would be much greater.

Statistical analysis
Fisher’s exact test was used to determine whether the proportion of PTV carriers for individual genes was different between two of the largest ethnic subgroups in this study (i.e., Chinese and Malay). To test for associations between PTV carrier ship and tumor characteristics in the full analytical cohort of 8852 breast cancer patients, we carried out multinomial logistic regression analyses (multinom function in the R package “nnet”) with tumor characteristics as the outcome, adjusting for age at diagnosis, study, and ethnicity. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated. While SGBCC and MyBrCa included three core ethnic groups, KOHBRA consisted of a homogeneous population of Koreans; hence, adjustment for study and ethnicity was done as a joint variable.

Overall survival was studied in a subset of patients (n = 6477, 73% of analytical cohort, KOHBRA study excluded). Additional file 1: Fig. S2 and Fig. S3 show the Kaplan-Meier curves including and excluding KOHBRA excluded). Additional file 1: Table S3 presents the characteristics of the 8852 breast cancer patients by study cohort.

PTV gene subset analysis
In the recent study by Dorling et al. [13] involving 60,466 female breast cancer cases and 53,461 controls from 44 studies, PTVs in nine of the 34 genes (ATM, BRCA1, BRCA2, CHEK2, PALB2, BARD1, RAD51C, RAD51D, and TP53) were found to be strongly associated with breast cancer risk (Bayesian false-discovery probability, <0.05). Association and survival analyses were repeated for PTV carrier ship coded for these nine genes and separately for the remaining 25 genes. In the analysis of the remaining 25 genes, carriers of any of the nine genes associated with breast cancer risk were excluded.

PTV subset analysis
As BRCA1/2 carriers tend to be associated with more aggressive tumor characteristics [15], all analyses were repeated without BRCA1/2 carriers to assess the combined effect of other breast cancer predisposition genes.

Intrinsic breast tumor subtypes are known to be highly predictive with breast cancer survival [16]. In addition, heterogeneity has been observed for breast cancer susceptibility risk genes across clinical subtypes for breast cancer [13, 17]. Hence, we performed further analysis to study the association of PTV carrier ship with tumor characteristics and survival was within each proxy subtype (luminal A, luminal B [HER2−], luminal B [HER2+], HER2-enriched [HER2+], and triple-negative).

As ethnic Chinese breast cancer patients comprise the majority of the study population (71%), all analyses were repeated on a subset of 6265 Chinese breast cancer patients.

All statistical analyses were performed using R version 4.0.2.

Results
Characteristics of the breast cancer cohorts
Table 1 summarizes the characteristics of the 8852 breast cancer patients included in this study. The median age at diagnosis was 51 years (interquartile range [IQR] 44 to 59). Incident cases made up 59% of all the breast cancer patients. The majority of the patients were Chinese (71%), followed by Malay (14%), Indian (8%), and Korean (6%). Fourteen percent of the patients reported having a family history of breast cancer. Additional file 1: Table S3 presents the characteristics of patients by study cohort.
PTV-associated tumors were phenotypically more aggressive

Approximately 11% of breast cancer patients (979 carriers) carried at least one PTV among the 34 genes sequenced (prevalence of 8% in Chinese, 9% in Malay, 9% in Indian, and 50% in Korean [KOHBRA was enriched for BRCA1/2 carriers]) (Table 1). The proportion of PTV carriers in four genes were significantly different between Chinese and Malay breast cancer patients (Fisher’s exact test, $BRCA1$, $p = 0.009$;

### Table 1 Characteristics of breast cancer patients. IQR

| Demographics               | N (%) | Grade                          | N (%) |
|----------------------------|-------|--------------------------------|-------|
| **Study**                  |       | Well-differentiated            | 1029 (12%) |
| SGRBCC                     | 4529 (51%) | Moderately differentiated    | 3284 (37%) |
| MyBrCa                     | 3761 (42%) | Poorly differentiated         | 3038 (34%) |
| KOHBRA                     | 562 (6%)   | Unknown                        | 1501 (17%) |
| **Case type**              |       |                                |       |
| Incident                   | 5229 (59%) | Positive                       | 5542 (63%) |
| Prevalent                  | 3587 (41%) | Negative                       | 2242 (25%) |
| Unknown                    | 36 (0%)     | Unknown                        | 1068 (12%) |
| **Median age at diagnosis (IQR)** |       |                                |       |
| Unknown                    | 51 (44–59) | Positive                       | 4722 (53%) |
| **Ethnicity**              |       | Negative                       | 2820 (32%) |
| Chinese                    | 6265 (71%) | Unknown                        | 1310 (15%) |
| Malay                      | 1213 (14%) |                                |       |
| Indian                     | 707 (8%)   |                                |       |
| Korean                     | 562 (6%)   |                                |       |
| Others                     | 86 (1%)    |                                |       |
| Unknown                    | 19 (0%)    |                                |       |
| **Family history**         |       |                                |       |
| No                         | 6968 (79%) | Luminal A                      | 2448 (28%) |
| Yes                        | 1220 (14%) | Luminal B [HER2–]              | 837 (9%)   |
| Unknown                    | 664 (8%)   | Luminal B [HER2+]              | 1033 (12%) |
| **Tumor characteristics**  |       | HER2-overexpressed             | 757 (9%)   |
| **Stage**                  |       | triple-negative                | 914 (10%)   |
| 0                          | 759 (9%)   | Unknown                        | 2863 (32%) |
| I                          | 2244 (25%) |                                |       |
| II                         | 2746 (31%) |                                |       |
| III                        | 1123 (13%) |                                |       |
| IV                         | 270 (3%)   |                                |       |
| Unknown                    | 1710 (19%) |                                |       |
| **Nodal status**           |       | Protein-truncating variants (PTVs) |       |
| Negative                   | 4765 (54%) | PTV 34 genes                   |       |
| Positive                   | 2889 (33%) | Non-carrier                    | 7873 (89%) |
| Unknown                    | 1198 (14%) | Carrier                        | 979 (11%) |
| **Tumor size, cm**         |       | PTV 9 genes                    |       |
| ≤2                         | 1171 (13%) | Non-carrier                    | 8162 (92%) |
| 2–5                        | 1837 (21%) | Carrier                        | 690 (8%)   |
| >5                         | 3916 (44%) |                                |       |
| Unknown                    | 1928 (22%) |                                |       |
| ≥25                        | 1171 (13%) | PTV 25 genes                   |       |
| 2–5                        | 1837 (21%) | Non-carrier                    | 8524 (96%) |
| >5                         | 3916 (44%) | Carrier                        | 328 (4%)   |

PTV-associated tumors were phenotypically more aggressive

Approximately 11% of breast cancer patients (979 carriers) carried at least one PTV among the 34 genes sequenced (prevalence of 8% in Chinese, 9% in Malay, 9% in Indian, and 50% in Korean [KOHBRA was enriched for BRCA1/2 carriers]) (Table 1). The proportion of PTV carriers in four genes were significantly different between Chinese and Malay breast cancer patients (Fisher’s exact test, $BRCA1$, $p = 0.009$;
**BRCA2**, \(p = 0.008\); **MUTYH**, \(p = 2.65E-4\); **MSH6**, \(p = 0.003\), Additional file 1: Table S4). The proportion of **BRCA1** carriers were approximately twofold higher in Malay breast cancer patients compared to Chinese breast cancer patients. **MUTYH** PTVs were more common in Malay patients while **MSH6** PTVs were more common in Chinese patients. However, multiple testing for 34 genes needs to be considered when interpreting these results.

Compared to tumors in breast cancer patients without any predicted **PTV34genes** (adjusted for age at diagnosis, study, and ethnicity), tumors of **PTV34genes** carriers were more likely to be of advanced stage (**ORstage II vs stage I** 1.34 [1.10 to 1.63], **ORstage III vs stage I** 1.29 [1.00 to 1.66]), more likely to be invasive (vs in situ, **OR** 1.48 [1.15 to 1.91]), node-negative (vs node-positive, **OR** 1.28 [1.10 to 1.49]), higher grade (poorly vs well-differentiated, **OR** 1.64 [1.26 to 2.14]), larger (**OR5 vs ≤2cm** 1.47 [1.11 to 1.93], **OR2−5 vs ≤2cm** 1.39 [1.09 to 1.77]), ER-negative (vs ER-positive, **OR** 1.40 [1.19 to 1.64]), PR-negative (vs PR-positive, **OR** 1.40 [1.20 to 1.64]), and HER2-negative (vs HER2-positive, **OR** 1.42 [1.17 to 1.73]) (Table 2). In addition, **PTV**-associated tumors were more often of luminal B [HER2−] (vs luminal A, **OR** 1.68 [1.30 to 2.18]) and triple-negative subtypes (vs luminal A, **OR** 2.22 [1.76 to 2.80]). After the exclusion of 522 **BRCA1/2** carriers, stage (**ORstage II vs stage I** 1.33 [1.03 to 1.72]), tumor size (**OR2−5cm vs ≤2cm** 1.92 [1.33 to 2.77]), and subtype (**ORluminal B [HER2−] vs luminal A** 1.46 [1.04 to 2.05]) remained significantly associated with **PTV34genes carriership** (Table 2).

Compared to **PTV34genes** carriership, the observed associations with tumor characteristics were generally larger in effect size when **PTV9genes** carriership (i.e., nine genes found to be significant in Dorling et al. [18]) was evaluated (Table 3). After the omission of **BRCA1/2** carriers from the analysis, stage (**ORstage II vs stage I** [95% CI] 1.86 [1.20 to 2.87]), grade (**OR**poorly vs well-differentiated [95% CI] 3.67 [1.77 to 7.62]), size (**OR5cm vs ≤2cm** 2.03 [1.02 to 4.04]), and subtype (**ORluminal B [HER2−] vs luminal A** 2.37 [1.44 to 3.91] and **OR**triple-negative vs luminal A 1.90 [1.12 to 3.23]) remained significantly associated with **PTV9genes carriership** (Table 3).

Similar to **PTV9genes carriership** after the exclusion of **BRCA1/2** carriers, **PTV25genes carriership** of the remaining 25 genes was not significantly associated with most tumor characteristics, with the exception of tumor size (**OR2−5cm vs ≤2cm** 1.84 [1.18 to 2.86]) (Table 3). Grade was also significantly associated with **PTV25genes carriership**, but in the opposite direction grade (**OR**moderately vs well-differentiated [95% CI] 0.65 [0.46 to 0.92], **OR**poorly vs well-differentiated [95% CI] 0.69 [0.48 to 0.97]).

We further conducted subset analyses to evaluate the relationship between **PTV** carriership and tumor characteristics within subgroups of patients with breast cancer of different proxy subtypes (Table S5). Among patients of luminal A subtype, **PTV34genes** and **PTV9genes carriership** were associated with stage (**PCumulative logistic regression** = 0.010 and 0.008, respectively) and nodal status (**OR**positive vs negative 1.79 [1.31 to 2.45] and 1.95 [1.30 to 2.92], respectively). Among patients of luminal B [HER2+] subtype, **PTV34genes** and **PTV9genes carriership** were associated with tumor size (**PCumulative logistic regression** = 0.013 and 0.008, respectively).

**PTV** carriership and overall survival within 10 years post-diagnosis

In 6477 invasive non-metastatic breast cancer patients aged <75 years at diagnosis from SGBCC and MyBrCa, a total of 790 deaths due to any cause occurred within 10 years after diagnosis with a median follow-up time of ~5.6 years (IQR 3.4 to 8.5). The 10-year overall survival rate was 75% (95% CI 74 to 77%). In these 6477 patients, associations between **PTV** carriership and tumor characteristics were found to be similar with those from the entire analytical cohort of 8852 patients (Additional file 1: Table S6). Population structure of the major ethnic groups in SGBCC and MyBrCa was largely similar; Additional file 1: Fig. S4 shows a principal component analysis plot of SGBCC and MyBrCa breast cancer patients, colored by study (SGBCC or MyBrCa) and denoted by ethnicity (Chinese, Malay, or Indian).

**PTV34genes** was not found to be associated with 10-year overall survival (Additional file 1: Table S7, Fig. S5). The results were not appreciably different after adjustment for age at diagnosis, study, ethnicity, stage, grade, ER status, nodal status, and tumor size or when **BRCA1/2** carriers were excluded (Additional file 1: Table S7, Table 4, and Additional file 1: Fig. S6).

**PTV9genes carriership** was not significantly associated with 10-year overall survival (Additional file 1: Table S7 and Fig. S7). After adjusting for age at diagnosis, study, ethnicity, stage, grade, ER status, nodal status, and tumor size, **PTV9genes carriership** (HR 0.54 [0.32 to 0.92]) was associated with better overall survival in older breast cancer patients (50 to 75 years) (Table 4). Among younger patients, the **HR** (95% CI) was 0.92 (0.63 to 1.34) (\(p = 0.654\)). The protective effect among older patients remained significant when only **BRCA1/2** PTVs were considered in the gene subset (**HR** 0.42 [0.19 to 0.94], \(p = 0.035\)).

In contrast, **PTV25genes carriership** was significantly associated with 10-year overall survival in the analysis including breast cancer patients of any age (adjusted **HR** 1.63 [1.16 to 2.28], Table 4). The effect size was larger for older breast cancer patients (adjusted **HR** 1.77 [1.13 to 2.79]) compared to younger patients (adjusted **HR** 1.48 [0.89 to 2.46], \(p = 0.131\), Table 4 and Additional file...
### Table 2  Associations between protein-truncating variant [PTV] carriership (34 genes) and demographics, and tumor characteristics

| Demographics | (i) PTV 34 genes excluding BRCA1/2 carriers | (ii) PTV 34 genes—excluding BRCA1/2 carriers |
|--------------|------------------------------------------|--------------------------------------------|
|              | Non-carrier | Carrier | OR (95% CI) | p     | Non-carrier | Carrier | OR (95% CI) | p     |
| **Family history** | | | | | | | | |
| No           | 6437        | 531     | 1.00 (reference) | | 6437        | 346     | 1.00 (reference) | | |
| Yes          | 1061        | 159     | 1.89 (1.56 to 2.29) | <0.001 | 1061        | 81      | 1.43 (1.12 to 1.84) | 0.005 |
| Unknown      | 375         | 289     | 2.08 (1.27 to 3.41) | 0.004  | 375         | 30      | 1.26 (0.61 to 2.58) | 0.531 |
| **Age group** | | | | | | | | (adjusted for ethnicity and study) |
| ≥50          | 4453        | 389     | 1.00 (reference) | | 4453        | 245     | 1.00 (reference) | | |
| <50          | 3394        | 586     | 1.36 (1.17 to 1.58) | <0.001 | 3394        | 209     | 1.09 (0.90 to 1.32) | 0.384 |
| Missing age  | 26          | 4       | 2.61 (0.84 to 8.06) | 0.096  | 26          | 3       | 3.23 (0.88 to 11.83) | 0.077 |
| **Ethnicity** | | | | | | | | (adjusted for age at diagnosis only) |
| Chinese (MyBrCa) | 2361 | 227 | 1.00 (reference) | | 2361 | 142 | 1.00 (reference) | | |
| Chinese (SGBCC) | 3390 | 287 | 0.91 (0.76 to 1.10) | 0.341 | 3390 | 202 | 1.01 (0.81 to 1.26) | 0.955 |
| Malay (MyBrCa) | 556 | 63 | 1.07 (0.79 to 1.44) | 0.676 | 556 | 25 | 0.71 (0.45 to 1.10) | 0.124 |
| Malay (SGBCC) | 542 | 52 | 1.00 (0.73 to 1.37) | 0.989 | 542 | 31 | 0.95 (0.64 to 1.42) | 0.818 |
| Indian (MyBrCa) | 404 | 48 | 1.25 (0.90 to 1.74) | 0.185 | 404 | 26 | 1.08 (0.70 to 1.66) | 0.729 |
| Indian (SGBCC) | 238 | 17 | 0.78 (0.47 to 1.30) | 0.338 | 238 | 4 | 0.28 (0.10 to 0.78) | 0.014 |
| Korean        | 282         | 280     | **8.38 (6.68 to 10.50)** | <0.001 | 282         | 24      | 1.28 (0.80 to 2.04) | 0.308 |
| Others/unknown | 100        | 5       | 0.51 (0.18 to 1.39) | 0.187  | 100         | 3       | 0.40 (0.10 to 1.63) | 0.199 |
| **Tumor characteristics** | | | | | | | | |
| **Stage** | | | | | | | | |
| 0            | 703         | 56      | 0.83 (0.60 to 1.14) | 0.247  | 703         | 34      | 0.96 (0.64 to 1.43) | 0.822 |
| I            | 2038        | 206     | 1.00 (reference) | | 2038        | 103     | 1.00 (reference) | | |
| II           | 2421        | 325     | **1.34 (1.10 to 1.63)** | 0.003  | 2421        | 161     | **1.33 (1.03 to 1.72)** | 0.028 |
| III          | 1007        | 116     | **1.29 (1.00 to 1.66)** | 0.047  | 1007        | 61      | 1.23 (0.89 to 1.70) | 0.216 |
| IV           | 240         | 30      | 1.49 (0.98 to 2.26) | 0.064  | 240         | 11      | 0.96 (0.50 to 1.81) | 0.889 |
| Unknown      | 1464        | 246     | **1.30 (1.05 to 1.61)** | 0.015  | 1464        | 87      | 1.14 (0.85 to 1.54) | 0.379 |
| **Cumulative logistic model** | 6409 | 733 | **1.32 (1.14 to 1.52)** | <0.001 | 6409 | 370 | **1.18 (0.98 to 1.42)** | 0.090 |
| **Tumor behavior** | | | | | | | | |
| In situ      | 949         | 79      | 1.00 (reference) | | 949         | 43      | 1.00 (reference) | | |
| Invasive     | 6628        | 850     | **1.48 (1.15 to 1.91)** | 0.003  | 6628        | 401     | 1.35 (0.97 to 1.87) | 0.073 |
| Unknown      | 296         | 50      | 1.13 (0.74 to 1.72) | 0.583  | 296         | 13      | 0.74 (0.36 to 1.50) | 0.401 |
| **Nodal status** | | | | | | | | |
| Negative     | 4282        | 483     | 1.00 (reference) | | 4282        | 240     | 1.00 (reference) | | |
| Positive     | 2519        | 370     | **1.28 (1.10 to 1.49)** | 0.002  | 2519        | 168     | 1.20 (0.98 to 1.47) | 0.081 |
| Unknown      | 1072        | 126     | 0.89 (0.71 to 1.11) | 0.290  | 1072        | 49      | 0.78 (0.56 to 1.07) | 0.127 |
| **Grade** | | | | | | | | |
| Well-differentiated | 947 | 82 | 1.00 (reference) | | 947 | 58 | 1.00 (reference) | | |
| Moderately differentiated | 2980 | 304 | 1.23 (0.94 to 1.61) | 0.131  | 2980 | 154 | 0.85 (0.62 to 1.16) | 0.311 |
| Poorly differentiated | 2672 | 366 | **1.64 (1.26 to 2.14)** | <0.001 | 2672 | 177 | 1.09 (0.80 to 1.48) | 0.577 |
| Unknown      | 1274        | 227     | 1.25 (0.94 to 1.68) | 0.124  | 1274        | 68      | 0.81 (0.56 to 1.18) | 0.272 |
| **Cumulative logistic model** | 6599 | 752 | **1.41 (1.21 to 1.64)** | <0.001 | 6599 | 389 | 1.16 (0.95 to 1.41) | 0.140 |
The likelihood ratio tests (LRT) for interaction between PTV and age group (<50 years, 50 to 75 years) in the adjusted models (study, ethnicity, stage, grade, ER status, nodal status, and tumor size) were not statistically significant ($p$-values, PTV34genes 0.507, PTV9genes 0.084, and PTV25genes 0.556). Further adjustments for treatment variables for all survival analyses did not appreciably change the results (Additional file 1: Table S9).

Kaplan-Meier curves for 10-year overall survival within each proxy subtype are presented in Additional file 1: Fig. S9 to S11. Significant associations were observed between PTV34genes and PTV25genes carriership and worse 10-year overall survival in the HER2-overexpressed proxy subtype. However, it should be noted that the results have to be interpreted with caution due to the limited number of death events within each subgroup.

**Subset analysis in Chinese breast cancer patients**

The results observed for Chinese breast cancer patients were similar to that of all breast cancer patients, for associations between PTV carriership and tumor characteristics and also associations between PTV carriership and survival. While the $p$-values were no longer statistically significant due to the reduced sample size comprising only Chinese breast cancer patients, the observed odds ratios and hazard ratios were not appreciably different. These results are presented in Additional file 1: Tables S9 and S10.

**Discussion**

Evaluating disease associations for rare variants in standard single-variant association analysis is challenging, since even if the effect size is large, the statistical power may still be low [19]. However, grouping variants in

| Tumor size, cm | Non-carrier | Carrier | OR (95% CI) | $p$ | Non-carrier | Carrier | OR (95% CI) | $p$
|----------------|------------|---------|-------------|----|------------|---------|-------------|----|
| $\leq$ 2       | 1019       | 152     | 1.00 (reference) |    | 1019       | 41      | 1.00 (reference) |    |
| 2–5            | 1599       | 238     | 1.39 (1.09 to 1.77) | 0.007 | 1599       | 119     | 1.92 (1.33 to 2.77) | <0.001 |
| $>5$           | 3582       | 334     | 1.47 (1.11 to 1.93) | 0.007 | 3582       | 205     | 1.48 (0.98 to 2.23) | 0.060 |
| Unknown        | 1673       | 255     | 1.36 (1.06 to 1.74) | 0.014 | 1673       | 92      | 1.38 (0.93 to 2.05) | 0.108 |
| Cumulative logistic model | 6200 | 724 | 1.24 (1.02 to 1.50) | 0.030 | 6200 | 365 | 1.20 (0.92 to 1.55) | 0.177 |

| Estrogen receptor status | Non-carrier | Carrier | OR (95% CI) | $p$ | Non-carrier | Carrier | OR (95% CI) | $p$
|--------------------------|------------|---------|-------------|----|------------|---------|-------------|----|
| Positive                 | 5034       | 508     | 1.00 (reference) |    | 5034       | 283     | 1.00 (reference) |    |
| Negative                 | 1933       | 309     | 1.40 (1.19 to 1.64) | <0.001 | 1933       | 121     | 1.11 (0.89 to 1.38) | 0.368 |
| Unknown                  | 906        | 162     | 1.20 (0.97 to 1.49) | 0.092 | 906        | 53      | 0.96 (0.70 to 1.31) | 0.786 |

| Progesterone receptor status | Non-carrier | Carrier | OR (95% CI) | $p$ | Non-carrier | Carrier | OR (95% CI) | $p$
|------------------------------|------------|---------|-------------|----|------------|---------|-------------|----|
| Positive                    | 4296       | 426     | 1.00 (reference) |    | 4296       | 232     | 1.00 (reference) |    |
| Negative                    | 2461       | 359     | 1.40 (1.20 to 1.64) | <0.001 | 2461       | 149     | 1.13 (0.91 to 1.40) | 0.257 |
| Unknown                     | 1116       | 194     | 1.33 (1.09 to 1.62) | 0.005 | 1116       | 76      | 1.20 (0.91 to 1.57) | 0.200 |

| HER2 receptor status        | Non-carrier | Carrier | OR (95% CI) | $p$ | Non-carrier | Carrier | OR (95% CI) | $p$
|-----------------------------|------------|---------|-------------|----|------------|---------|-------------|----|
| Positive                    | 1735       | 159     | 1.00 (reference) |    | 1735       | 108     | 1.00 (reference) |    |
| Negative                    | 4061       | 584     | 1.42 (1.17 to 1.73) | <0.001 | 4061       | 235     | 0.93 (0.73 to 1.18) | 0.537 |
| Unknown                     | 2077       | 236     | 1.12 (0.90 to 1.40) | 0.302 | 2077       | 114     | 0.85 (0.65 to 1.12) | 0.254 |

| Proxy subtype               | Non-carrier | Carrier | OR (95% CI) | $p$ | Non-carrier | Carrier | OR (95% CI) | $p$
|------------------------------|------------|---------|-------------|----|------------|---------|-------------|----|
| Luminal A                   | 2244       | 204     | 1.00 (reference) |    | 2244       | 113     | 1.00 (reference) |    |
| Luminal B [HER2−]           | 729        | 108     | 1.68 (1.30 to 2.18) | <0.001 | 729        | 52      | 1.46 (1.04 to 2.05) | 0.029 |
| Luminal B [HER2+]           | 947        | 86      | 0.97 (0.74 to 1.27) | 0.823 | 947        | 59      | 1.24 (0.90 to 1.72) | 0.196 |
| HER2-overexpressed          | 705        | 52      | 0.83 (0.60 to 1.15) | 0.272 | 705        | 36      | 1.02 (0.69 to 1.50) | 0.912 |
| Triple-negative             | 727        | 187     | 2.22 (1.76 to 2.80) | <0.001 | 727        | 51      | 1.38 (0.98 to 1.95) | 0.065 |
| Unknown                     | 2521       | 342     | 1.20 (0.98 to 1.45) | 0.072 | 2521       | 146     | 1.12 (0.86 to 1.44) | 0.400 |

Models are adjusted for age at diagnosis (years) and the joint variable of study and ethnicity. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multinomial logistic regression models with each tumor characteristic as the outcome and genetic factors as explanatory variables; patients with unknown values were excluded from the analysis. $p$-value from Wald test. Results associated with $p < 0.05$ are denoted in bold.
### Table 3: Associations between protein-truncating variant (PTV) carriership (9 and 25 genes) and tumor characteristics

|                      | (i) 9 genes |                      | (ii) 9 genes—excluding BRCA1/2 carriers | (iii) 25 genes |
|----------------------|-------------|----------------------|----------------------------------------|---------------|
|                      | Non-carrier | Carrier              | OR (95% CI)    | p     | Non-carrier | Carrier | OR (95% CI)    | p     | Non-carrier | Carrier | OR (95% CI)    | p     |
| **Stage**            |             |                      |              |       |             |         |              |       |             |         |              |       |
| 0                    | 727         | 32                   | 0.75 (0.49 to 1.14) | 0.182 | 727         | 10      | 0.99 (0.48 to 2.05) | 0.987 | 703         | 24      | 0.94 (0.58 to 1.50) | 0.79 |
| I                    | 2111        | 133                  | 1.00 (reference) |       | 2111        | 30      | 1.00 (reference) |       | 2038        | 73      | 1.00 (reference) |       |
| II                   | 2516        | 230                  | **1.48 (1.17 to 1.88)** | **0.001** | 2516        | 66      | **1.86 (1.20 to 2.87)** | **0.006** | 2421        | 95      | 1.11 (0.81 to 1.52) | 0.504 |
| III                  | 1047        | 76                   | 1.36 (1.00 to 1.86) | 0.051 | 1047        | 21      | 1.41 (0.80 to 2.49) | 0.23  | 1007        | 40      | 1.15 (0.78 to 1.71) | 0.478 |
| IV                   | 248         | 22                   | **1.85 (1.13 to 3.02)** | **0.015** | 248         | 3       | 0.89 (0.27 to 2.93) | 0.844 | 240         | 8       | 0.98 (0.47 to 2.07) | 0.961 |
| Missing              | 1513        | 197                  | 1.54 (1.19 to 1.98) | <0.001 | 1513        | 38      | 1.74 (1.06 to 2.84) | 0.028 | 1464        | 49      | 0.91 (0.62 to 1.32) | 0.61  |
| **Cumulative logistic model** | 6649 | 493                  | **1.43 (1.20 to 1.70)** | <0.001 | 6649        | 130     | 1.29 (0.95 to 1.75) | 0.108 | 6409        | 192     | 1.03 (0.79 to 1.33) | 0.83  |
| **Tumor behavior**   |             |                      |              |       |             |         |              |       |             |         |              |       |
| In situ              | 979         | 49                   | 1.00 (reference) |       | 979         | 13      | 1.00 (reference) |       | 949         | 30      | 1.00 (reference) |       |
| Invasive             | 6878        | 600                  | **1.64 (1.19 to 2.26)** | **0.003** | 6878        | 151     | 1.62 (0.91 to 2.88) | 0.102 | 6628        | 250     | 1.22 (0.83 to 1.81) | 0.309 |
| Missing              | 305         | 41                   | 1.00 (0.79 to 1.21) | **0.002** | 305         | 4       | 0.50 (0.11 to 2.26) | 0.37  | 296         | 9       | 0.84 (0.38 to 1.86) | 0.662 |
| **Nodal status**     |             |                      |              |       |             |         |              |       |             |         |              |       |
| Negative             | 4438        | 327                  | 1.00 (reference) |       | 4438        | 84      | 1.00 (reference) |       | 4282        | 156     | 1.00 (reference) |       |
| Positive             | 2623        | 266                  | **1.34 (1.12 to 1.61)** | **0.002** | 2623        | 64      | 1.28 (0.92 to 1.79) | 0.139 | 2519        | 104     | 1.15 (0.89 to 1.49) | 0.283 |
| Missing              | 1101        | 97                   | 0.97 (0.75 to 1.27) | 0.848 | 1101        | 20      | 0.89 (0.53 to 1.48) | 0.643 | 1072        | 29      | 0.72 (0.48 to 1.09) | 0.121 |
| **Grade**            |             |                      |              |       |             |         |              |       |             |         |              |       |
| Well-differentiated  | 997         | 32                   | 1.00 (reference) |       | 997         | 8       | 1.00 (reference) |       | 947         | 50      | 1.00 (reference) |       |
| Moderately           | 3080        | 204                  | **2.33 (1.56 to 3.49)** | **<0.001** | 3080        | 54      | 2.15 (1.02 to 4.54) | 0.045 | 2980        | 100     | 0.65 (0.46 to 0.92) | 0.015 |
| Poorly               | 2767        | 271                  | **3.48 (2.35 to 5.17)** | **<0.001** | 2767        | 82      | **3.67 (1.77 to 7.62)** | **<0.001** | 2672        | 95      | **0.69 (0.48 to 0.97)** | **0.036** |
| differentiated       |             |                      |              |       |             |         |              |       |             |         |              |       |
| Missing              | 1318        | 183                  | 2.42 (1.60 to 3.66) | <0.001 | 1318        | 24      | 2.05 (0.90 to 4.65) | 0.087 | 1274        | 44      | 0.62 (0.41 to 0.95) | 0.028 |
| **Cumulative logistic model** | 6844 | 507                  | **1.88 (1.56 to 2.26)** | **<0.001** | 6844        | 144     | **2.04 (1.48 to 2.82)** | **<0.001** | 6599        | 193     | 0.89 (0.68 to 1.17) | 0.411 |
| **Tumor size, cm**   |             |                      |              |       |             |         |              |       |             |         |              |       |
| ≤2                   | 1047        | 124                  | 1.00 (reference) |       | 1047        | 13      | 1.00 (reference) |       | 1019        | 28      | 1.00 (reference) |       |
| 2–5                  | 1677        | 160                  | 1.19 (0.90 to 1.56) | 0.229 | 1677        | 41      | **2.03 (1.08 to 3.81)** | **0.028** | 1599        | 78      | **1.84 (1.18 to 2.86)** | **0.007** |
| >5                   | 3712        | 204                  | **1.57 (1.14 to 2.17)** | **0.006** | 3712        | 75      | **2.03 (1.02 to 4.04)** | **0.044** | 3582        | 130     | 1.23 (0.75 to 2.04) | 0.415 |
| Missing              | 1726        | 202                  | **1.44 (1.10 to 1.90)** | **0.009** | 1726        | 39      | 2.02 (1.04 to 3.90) | 0.037 | 1673        | 53      | 1.10 (0.68 to 1.80) | 0.693 |
| **Cumulative logistic model** | 6436 | 488                  | **1.34 (1.07 to 1.69)** | **0.012** | 6436        | 129     | 1.54 (1.00 to 2.37) | 0.05  | 6200        | 187     | 1.11 (0.78 to 1.58) | 0.55  |
### Table 3

Associations between protein-truncating variant [PTV] carriership (9 and 25 genes) and tumor characteristics (Continued)

| i) 9 genes | ii) 9 genes—excluding BRCA1/2 carriers | iii) 25 genes |
|------------|----------------------------------------|---------------|
|            | Non-carrier | Carrier | OR (95% CI) | p   | Non-carrier | Carrier | OR (95% CI) | p   | Non-carrier | Carrier | OR (95% CI) | p   |
| Estrogen receptor status | | | | | | | | | | | | | |
| Positive   | 5218 | 324 | 1.00 (reference) | | 5218 | 99 | 1.00 (reference) | | 5034 | 184 | 1.00 (reference) | |
| Negative   | 2003 | 239 | 1.66 (1.37 to 2.00) | <0.001 | 2003 | 51 | 1.34 (0.95 to 1.89) | 0.095 | 1933 | 70 | 0.98 (0.74 to 1.30) | 0.908 |
| Missing    | 941 | 127 | 1.34 (1.04 to 1.72) | 0.021 | 941 | 18 | 0.92 (0.54 to 1.58) | 0.773 | 906 | 35 | 0.97 (0.67 to 1.42) | 0.895 |
| Progesterone receptor status | | | | | | | | | | | | | |
| Positive   | 4448 | 274 | 1.00 (reference) | | 4448 | 80 | 1.00 (reference) | | 4296 | 152 | 1.00 (reference) | |
| Negative   | 2548 | 272 | 1.64 (1.36 to 1.98) | <0.001 | 2548 | 62 | 1.35 (0.96 to 1.89) | 0.08 | 2461 | 87 | 1.01 (0.77 to 1.33) | 0.924 |
| Missing    | 1166 | 144 | 1.40 (1.11 to 1.78) | 0.005 | 1166 | 26 | 1.16 (0.73 to 1.84) | 0.535 | 1116 | 50 | 1.21 (0.87 to 1.68) | 0.26 |
| HER2 receptor status | | | | | | | | | | | | | |
| Positive   | 1812 | 82 | 1.00 (reference) | | 1812 | 31 | 1.00 (reference) | | 1735 | 77 | 1.00 (reference) | |
| Negative   | 4203 | 442 | 2.12 (1.64 to 2.73) | <0.001 | 4203 | 93 | 1.30 (0.86 to 1.96) | 0.211 | 4061 | 142 | 0.78 (0.59 to 1.04) | 0.093 |
| Missing    | 2147 | 166 | 1.56 (1.17 to 2.08) | 0.002 | 2147 | 44 | 1.18 (0.74 to 1.90) | 0.486 | 2077 | 70 | 0.73 (0.52 to 1.02) | 0.061 |
| Proxy subtype | | | | | | | | | | | | | |
| Luminal A  | 2320 | 128 | 1.00 (reference) | | 2320 | 37 | 1.00 (reference) | | 2244 | 76 | 1.00 (reference) | |
| Luminal B [HER2−] | 753 | 84 | 2.15 (1.58 to 2.92) | <0.001 | 753 | 28 | 2.37 (1.44 to 3.91) | <0.001 | 729 | 24 | 1.01 (0.63 to 1.61) | 0.981 |
| Luminal B [HER2+] | 989 | 44 | 0.75 (0.52 to 1.09) | 0.133 | 989 | 17 | 1.08 (0.61 to 1.93) | 0.789 | 947 | 42 | 1.31 (0.89 to 1.92) | 0.175 |
| HER2-overexpressed | 732 | 25 | 0.63 (0.40 to 0.99) | 0.046 | 732 | 9 | 0.77 (0.37 to 1.60) | 0.483 | 705 | 27 | 1.15 (0.73 to 1.80) | 0.548 |
| Triple-negative | 755 | 159 | 2.85 (2.17 to 3.73) | <0.001 | 755 | 23 | 1.90 (1.12 to 3.23) | 0.018 | 727 | 28 | 1.13 (0.72 to 1.76) | 0.601 |
| Unknown    | 2613 | 250 | 1.30 (1.02 to 1.64) | 0.033 | 2613 | 54 | 1.27 (0.83 to 1.95) | 0.27 | 2521 | 92 | 1.04 (0.76 to 1.42) | 0.804 |

All models are adjusted for study, ethnicity, and age at diagnosis. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multinomial logistic regression models with each tumor characteristic as the outcome and genetic factors as explanatory variables. PTV9 genes includes *ATM*, *BRCA1*, *BRCA2*, *CHEK2*, *PALB2*, *BARD1*, *RAD51C*, *RAD51D*, and *TP53*. PTV25 genes includes *ABRAXIS1*, *AKT1*, *BABAM2*, *BRIP1*, *CDH1*, *EPCAM*, *FANCC*, *FANCM*, *GEN1*, *MEN1*, *MRE11A*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NBN*, *NF1*, *PIK3CA*, *PMS2*, *PIK3CA*, *RECQL*, *RINT1*, *SKT11*, and *XRCC2*. p-value from Wald test. Test for trend of stage, grade, and tumor size was done using the cumulative logistic model, excluding patients with missing values. Results associated with p < 0.05 are denoted in bold.
multimarker tests may substantially improve power [19]. For example, multiple common variants are frequently collapsed into a single polygenic risk score [20]. For rare variant analysis in a gene-based burden test, the number of individuals carrying variants in a given gene is compared between affected and unaffected groups [21]. While rare variant analyses are commonly carried out in a region or gene-based manner [13, 17], the collective effect of pathogenic variants across multiple breast cancer genes may also be studied [6, 22, 23]. In this large study of Asian breast cancer patients, we showed that PTV carriership in certain known or suggested breast cancer predisposition genes was associated with disease severity and fatality.

Two smaller studies on Asian Chinese breast cancer patients showed that while BRCA1/2 PTV carriers were associated with more aggressive clinical features, PTV carriers of non-BRCA1/2 breast cancer susceptibility genes when treated as a single group were not significantly associated with tumor characteristics (Wang et al., 480 patients, 65 PTV carriers for 20 genes [23]; Li et al., 936 patients, 223 PTV carriers for 40 genes [22]). However, in spite of differences in population ancestry, results from our large study of Asian breast cancer patients closely replicated the findings of a study comprising 5099 breast cancer patients of European descent [6]. The European study examined PTVs in 31 genes in an earlier version of the BRIDGES panel, of which 30 genes overlap with the 34 genes in our study. The overlap between the genes included in Li et al. [6] and the current study is shown in Additional file 1: Figure S12. Li et al. [6] reported that compared to non-carriers, PTV carriers were more likely to have more aggressive tumors (i.e., ER-negative, large size, high grade, highly proliferative, luminal B, and triple-negative subtype). We observed the same significant associations in our Asian study and additionally found significant associations between PTV carriership and disease stage, tumor behavior, nodal involvement, PR status, and HER2 status.

Taking into account the known associations between BRCA1/2-related tumors and worse tumor biology, all analyses were repeated excluding BRCA1/2 carriers. Li et al. [6] observed that PTV carriership remained associated with high grade and worse survival. In our study, a significant association with grade was no longer seen after BRCA1/2 carrier exclusion, but other tumor characteristics common of fast-growing tumors, such as stage, tumor size, and luminal B [HER2−] subtype, remained significant.

### Table 4 Associations between protein-truncating variant (PTV) carriership (34, 9, 25 genes) and overall survival

| (A) All ages | (B) <50 years | (C) 50 to 75 years |
|--------------|--------------|-------------------|
| Alive | Dead | HR (95% CI) | p | Alive | Dead | HR (95% CI) | p | Alive | Dead | HR (95% CI) | p |
| Non-carrier | 5213 | 710 | 1.00 (reference) | | 2152 | 308 | 1.00 (reference) | | 3061 | 402 | 1.00 (reference) | |
| Carrier | 474 | 80 | 1.03 (0.81 to 1.29) | 0.831 | 232 | 46 | 1.07 (0.78 to 1.46) | 0.677 | 242 | 34 | 0.92 (0.65 to 1.31) | 0.661 |

All Cox proportional hazard models are adjusted for age at diagnosis (years), study (SGBCC or MyBrCa), ethnicity (Chinese, Malay, Indian, or others), stage (I, II, or III), grade (well-, moderately, or poorly differentiated), estrogen receptor status (positive, negative), nodal status (positive, negative), and tumor size (≤5 cm, >5 cm). (A) All ages and subgroups of (B) age at diagnosis <50 and (C) age at diagnosis 50 to 75. Patients considered in each association studied are indicated as follows: (i) all breast cancer patients, (ii) excluding BRCA1 carriers, and (iii) excluding carriers of PTV9 genes (ATM, BRCA1, BRCA2, CHEK2, PALB2, BARD1, RAD51C, RAD51D, and TP53). Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) are shown. SD standard deviation.
A more recent study reported that not all of the 34 reported or known breast cancer susceptibility genes on the targeted sequencing panel were clinically relevant for the prediction of breast cancer risk [13]. The results of a subset analysis of the nine genes found to be associated with breast cancer risk suggest that the genes most relevant for breast cancer development were also associated with more aggressive tumor phenotypes (larger effect sizes observed than for 34 genes). Nonetheless, the worse tumor characteristics were mostly driven by BRCA1/2 carriers—only stage, size, and subtype remained significantly associated with PTV carriergship of the seven genes after the exclusion of BRCA1/2 carriers. PTV carriergship of the remaining 25 genes was associated with a larger tumor size. What we found to be different from the Li et al. [6] Swedish study was that in our study, among BRCA1/2 non-carriers, there was a null relationship between PTV carriergship (34 genes) and tumor grade. However, the gene subset analyses showed that while PTV genes carriergship predisposed patients to worse tumor grade, a larger proportion of PTV genes carriergship developed lower grade tumors.

We did not find a similar association between PTV genes carriergship and 10-year overall survival as reported in Li et al.’s work on a Swedish dataset of 5099 breast cancer patients [6]. Interestingly, the gene subset analyses showed that PTV carriergship of the nine genes, found to be most relevant for breast cancer risk, did not appear to be associated with worse survival. In particular, BRCA1/2 conferred a survival benefit for patients diagnosed above 50 years of age. PTV carriergship of the remaining 25 genes, however, increased the risk of dying from any cause in all age groups. This observation is unexpected as while PTV genes carriergship was associated with larger tumor size, the tumors were of a lower grade. A possible explanation could be that these 25 genes are associated with other cancers, for which we do not have information on to perform a competing risk analysis. An alternative explanation could be that some genes are important drivers of certain tumor subtypes associated with worse survival, which we do not have the statistical power to study. Further work in a larger study population, perhaps involving sub-analyses by further division of PTV genes carriergship, would be helpful in understanding this observation. Nonetheless, the results suggest that PTVs in breast cancer genes influence survival. Larger studies with higher statistical power will be needed to elucidate which of the genes are specifically associated with disease outcome.

The role of BRCA1/2 in survival among breast cancer patients has been studied widely [24, 25]. Most studies found that germline BRCA1/2 carriers were at a higher risk of death than their BRCA-negative counterpart, but there are indications that triple-negative breast cancer patients who are BRCA1/2 carriers have a better prognosis [23, 24, 26]. As BRCA1/2 carriergship has the potential to affect the efficacy of chemotherapy, the effect on survival will need to be interpreted in light of the standard of care and patient population studied [26].

Among South-East Asians, it has been observed that Malay breast cancer patients tend to develop more aggressive tumors and have poorer survival rates [27]. The survival difference has been attributed to ethnic differences in lifestyle, socio-economic status, cultural values, tumor biology, and response to treatment [27]. In a previous study comparing Chinese and Malay breast cancer patients, a higher prevalence of BRCA2 mutations was found among Malay breast cancer patients [28]. Our larger study supports this finding and found significant differences in the prevalence of some breast cancer genes (BRCA1, MSH6, and MUTYH) between the two ethnic groups, suggesting that germline genetics may impact ethnic differences in breast cancer tumor characteristics and survival. However, a larger study is needed to validate these ethnic differences.

There are limitations to this study. Although this study is the largest to date to examine the impact of rare variants on breast cancer tumor characteristics and survival among patients of Asian ancestry, the number of carriers is still too limited for individual gene evaluation. The numbers are also too small to make definitive conclusions in specific ethnic subgroups. The effect of large germline structural variants (e.g., deletions, duplications, insertions, inversions, and translocations), which are not limited to genetic changes in coding regions, was not evaluated in this study [29]. Such variants have been documented to contribute to 10–25% of pathogenic variants for hereditary disorders [29]. However, germline structural variants are less frequent in breast cancer genes such as BRCA1 (0.8 to 6.9%) and BRCA2 (5%) in Asian populations [30, 31]. As only germline variants were studied, we were not able to evaluate somatic second hits in tumors leading to the biallelic inactivation of the breast cancer genes. In view of potential bias, differences in the study design of each included cohort and how representative they are of the breast cancer demographics in general must be considered. For example, oversampling of BRCA1/2 carriers in the KOHIBRA study could have led to bias in the estimates, but limiting the analyses to two hospital-based cohorts (SGBCC and MyBrCa, unselected breast cancer patients) showed no evidence of such bias. Finally, we were not able to consider breast cancer-specific survival as the data was not consistently ascertained across all the studies.
However, it is noteworthy that this large Asian breast cancer population studied is novel and timely in view of possible Eurocentric biases in genetic studies [7, 32].

Conclusions

It is important to identify germline carriers of high-risk breast cancer PTVs to prioritize individuals for inclusion in cancer surveillance programs, which has the potential to save lives [33, 34]. The finding that PTV carriership is not just associated with higher breast cancer risk, but also more severe and fatal forms of the disease, suggests that genetic testing has the potential to provide additional health information and help healthy individuals make screening decisions.

Abbreviations

CI: Confidence interval; ER: Estrogen receptor; HER2: Human epidermal growth factor receptor; HR: Hazard ratio; KOHBRa: Korean Hereditary Breast Cancer Study; MyBrCa: Malaysian Breast Cancer Genetic Study; OR: Odds ratio; PR: Progesterone receptor; PTV: Protein-truncating variant; SGBCC: Singapore Breast Cancer Cohort

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13073-021-00978-9.

Additional file 1. Supplementary tables and figures. Description: This file contains Tables S1 to S10 and Fig. S1 to S12.

Acknowledgements

The study was made possible with the corporation of the participants and the assistance of research team members: from SGBCC—Jenny Liu, Siew Li Tan, Siok Hoon Yeo, Ting Ting Koh, Amanda Ong, Michelle Jia Qi Mo, Ying Jia Chew, Jin Yee Lee, Jing Jing Hong, Hui Min Lau, Ganga Devi D/O Chandrasegaran, Nur Khaliesah Binte Mohamed Ri, Nayli Nur Hannah Binte Mazlan, and Zi Lin Lim, and from the UMMC Breast Cancer Research Group—Mee Hoong See, Tania Islam, Mei Sze Teh, and Li Ying Teoh.

Authors’ contributions

Study design: JL, MH, and PJH; writing group: JL, PJH, MH, SHT, WKH, DFE, MKS, VMKT, BKT, and FYW; data management: PJH, JL, AJK, MCT, EAW, AMO, DFE, and MKS; statistical analysis: PJH, JL, WKH, and MKS; provided DNA samples and phenotypic data: MH, VMKT, BKT, SMT, YET, SHL, SHT, CHY, NAT, SI, YS, FYW, JN, SCL, CWC, SAB, PMYC, JJCC, JCMS, WPL, CWM, GHL, EY, SWK, JW, MHL, and SKP. All authors read and approved the final manuscript.

Funding

The sequencing and analysis for this project were funded by the European Union’s Horizon 2020 Research and Innovation Programme (BRIDGES: grant number 634935) and the Wellcome Trust [grant no: v203477/Z/16/Z]. SGBCC was supported by the National Research Foundation Singapore [NRF-NRF2017-02, awarded to J Li], NUS start-up Grant [awarded to MH], National University Cancer Institute Singapore (NCIS) Centre Grant [NMR/C/CG/NCIS/2010, NMR/C/CG/012/2013 and CGAug16M005, awarded to MH], Breast Cancer Prevention Programme (BCPP, awarded to MH), Asian Breast Cancer Research Fund [awarded to MH], and the NMRC Clinician Scientist Award (SI Category) [NMRC/CSCA-SI/0015/2017, awarded to MH], NMRC Centre Grant [CGAug16M012, awarded to EYT]. MyBrCa is funded by research grants from the Malaysian Ministry of Higher Education (UM/C/HIR/MOHE/O6), the Wellcome Trust [grant no: v203477/Z/16/2], and Cancer Research Malaysia.

Availability of data and materials

Data from each study were previously described (SGBCC [8], MyBrCa [9], and KOHBRa [10]). The genetic and clinical data used in this study were obtained via a data request (concept #680) to the Breast Cancer Association Consortium (BCAC). All data requests can be directed to the BCAC data access committee (http://bcac.ccf.ac.uk/bcaccdata/).

Declarations

Ethics approval and consent to participate

All studies were performed in accordance with the Declaration of Helsinki, and all participants provided written informed consent. SGBCC was approved by the National Healthcare Group Domain Specific Review Board (reference number: 2017/00797) and the SingHealth Centralised Institutional Review Board (reference number: 2016/3010). MyBrCa was approved by the Independent Ethics Committee, Ramsay Sirne Darby Health Care (reference number: 2011094 and 2012081), and the Medical Ethics Committee, University Malaya Medical Centre (reference number: MY239). KOHBRa has been reviewed and approved by the Institutional Review Board (reference number: B-0707-047-005) of each participating center.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Genome Institute of Singapore, Human Genetics, Singapore, Singapore. 2Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore. 3School of Mathematical Sciences, Faculty of Science and Engineering, University of Nottingham Malaysia, Jalan Broga, 43500 Semenyih, Selangor, Malaysia. 4Cancer Research Malaysia, 1 Jalan SS12/1A, 47500 Subang Jaya, Selangor, Malaysia. 5Subang Jaya Medical Centre, Jalan SS 12/1A, 47500 Subang Jaya, Selangor, Malaysia. 6Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia. 7UM Cancer Research Institute, Kuala Lumpur, Malaysia. 8Department of Breast Surgery, Singapore General Hospital, Singapore, Singapore. 9Division of Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore. 10Department of General Surgery, Sengkang General Hospital, Singapore, Singapore. 11Department of Breast Surgery, Changi General Hospital, Singapore, Singapore. 12Department of General Surgery, Tan Tock Seng Hospital, Singapore 308433, Singapore. 13Lee Kong Chian School of Medicine, Singapore, Singapore. 14Institute of Molecular and Cell Biology, Singapore, Singapore. 15K K Women’s and Children’s Hospital, Singapore 229899, Singapore. 16Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore. 17Lee Kong Chian School of Medicine, Nanyang Technology University, Singapore, Singapore. 18Cancer Genetics Service, National Cancer Centre Singapore, Singapore, Singapore. 19Oncology Academic Clinical Program, Duke NUS, Singapore, Singapore. 20Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore. 21Department of Hematology-oncology, National University Cancer Institute, National University Health System, Singapore 119074, Singapore. 22Department of Surgery, University Surgical Cluster, National University Hospital, Singapore, Singapore. 23Department of Surgery, Breast Care Center, Daerim St. Mary’s Hospital, Seoul, Korea. 24Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Republic of Korea. 25Department of Surgery, Soonchunhyang University and Hospital, Seoul, Republic of Korea. 26Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea. 27Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. 28Cancer Research Institute, Seoul National University, Seoul, Republic of Korea. 29Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK. 30Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. 31Division of Molecular Pathology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. 32Department of Surgery, Faculty of Medicine, University of Malaya, Jalan Universiti, 50630 Kuala Lumpur, Malaysia.

The online version contains supplementary material available at https://doi.org/10.1186/s13073-021-00978-9.
